Clinical trial • Phase III • Neurology|Oncology|Other
senicapoc for Glioblastoma|Malignant glioma|Glioblastoma multiforme
Phase III trial of senicapoc for Glioblastoma|Malignant glioma|Glioblastoma multiforme. 36 participants.
Overview
- Trial Therapeutic Area
- Neurology|Oncology|Other
- Trial Disease
- Glioblastoma|Malignant glioma|Glioblastoma multiforme
- Trial Stage
- Phase III
- Drug Modality
- Small molecule
Key dates
- Initial CTIS Submission Date
- 09-07-2025
- First CTIS Authorization Date
- 14-10-2025
Trial design
Phase III trial across 1 site in Denmark.
- Target Sample Size
- 36
Recruitment
- Planned Sample Size
- 36
- Recruitment Window Months
- 34
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 36
Denmark
- Earliest CTIS Part Ii Submission Date
- 24-09-2025
- Latest Decision Or Authorization Date
- 14-10-2025
- Processing Time Days
- 20
- Number Of Sites
- 1
- Number Of Participants
- 36
Sites
- Site Name
- Region Midtjylland
- Department Name
- Department of Neurosurgery
- Principal Investigator Name
- Anders Rosendal Korshøj
- Principal Investigator Email
- anders.r.korshoj@clin.au.dk
- Contact Person Name
- Anders Rosendal Korshøj
- Contact Person Email
- anders.r.korshoj@clin.au.dk
- Number Of Participants
- 36
Sponsor
Primary sponsor
- Full Name
- Region Midtjylland
- Organisation Type
- Hospital/Clinic/Other health care facility
- Country Of Registered Address
- Denmark
Investigational products
- Investigational Product Name
- senicapoc
- Active Substance
- senicapoc
- Modality
- Small molecule
- Investigational Product Name
- perampanel
- Active Substance
- perampanel
- Modality
- Small molecule
- Combination Treatment
- Yes
Related trials
Other published trials that may interest you.